These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 11998799

  • 21. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA, Vyssoulis GP, Karpanou EA, Marinakis AG, Barbetseas JD, Zervoudaki AI, Cokkinos DV, Stefanadis CI.
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [Abstract] [Full Text] [Related]

  • 22. Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 1: Antihypertensive therapy and left ventricular hypertrophy.
    Fagard R, Staessen J, Thijs L, Van Hoof R, Amery A.
    J Hypertens Suppl; 1993 Dec; 11(6):S27-9. PubMed ID: 7909547
    [No Abstract] [Full Text] [Related]

  • 23. Current issues in hypertension research and therapy.
    MacFadyen RJ, Prasad N.
    Br J Hosp Med; 1993 Dec; 53(7):335-43. PubMed ID: 7788073
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias].
    Antonio Francischetti E, Genelhu Fagundes V, Francischetti A.
    Arq Bras Cardiol; 1995 Dec; 65(6):555-63. PubMed ID: 8731314
    [No Abstract] [Full Text] [Related]

  • 27. Regression of left ventricular hypertrophy by spirapril.
    Eichstädt H, Sierakowski B, Eskötter H, Cordes M, Kreuz D.
    Blood Press Suppl; 1994 Dec; 2():93-4. PubMed ID: 8061856
    [No Abstract] [Full Text] [Related]

  • 28. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
    Devereux RB, Dahlof B, Levy D, Pfeffer MA.
    Am J Cardiol; 1996 Jul 01; 78(1):61-5. PubMed ID: 8712120
    [Abstract] [Full Text] [Related]

  • 29. Calcium-channel blockers for hypertension--uncertainty continues.
    Cutler JA.
    N Engl J Med; 1998 Mar 05; 338(10):679-81. PubMed ID: 9486999
    [No Abstract] [Full Text] [Related]

  • 30. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
    Tocci G, Palano F, Pagannone E, Chin D, Ferrucci A, Volpe M.
    Expert Rev Cardiovasc Ther; 2009 Feb 05; 7(2):115-23. PubMed ID: 19210207
    [Abstract] [Full Text] [Related]

  • 31. Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension.
    Pontremoli R, Viazzi F, Ravera M, Leoncini G, Berruti V, Bezante GP, Del Sette M, Deferrari G.
    J Nephrol; 2001 Feb 05; 14(1):19-26. PubMed ID: 11281339
    [Abstract] [Full Text] [Related]

  • 32. [Therapy for hypertension associated with heart failure].
    Miyamoto H, Imaizumi T.
    Nihon Naika Gakkai Zasshi; 2003 Feb 10; 92(2):258-63. PubMed ID: 12652730
    [No Abstract] [Full Text] [Related]

  • 33. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M, Martell Claros N, Study Investigators Group.
    Clin Ther; 2005 Feb 10; 27(2):166-73. PubMed ID: 15811479
    [Abstract] [Full Text] [Related]

  • 34. The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition.
    Pereira LM, Mandarim-De-Lacerda CA.
    Int J Exp Pathol; 2001 Apr 10; 82(2):115-22. PubMed ID: 11454102
    [Abstract] [Full Text] [Related]

  • 35. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC, El Aouar LM, Mill JG.
    Arq Bras Cardiol; 2000 Feb 10; 74(2):103-17. PubMed ID: 10904284
    [Abstract] [Full Text] [Related]

  • 36. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
    Yoshida C, Goda A, Naito Y, Nakaboh A, Matsumoto M, Otsuka M, Ohyanagi M, Hirotani S, Lee-Kawabata M, Tsujino T, Masuyama T.
    J Hypertens; 2011 Feb 10; 29(2):357-63. PubMed ID: 21052021
    [Abstract] [Full Text] [Related]

  • 37. Treatment of hypertension in the very old.
    Otterstad JE, Ruilope LM.
    Int J Clin Pract Suppl; 2000 Nov 10; (114):10-9. PubMed ID: 11221289
    [Abstract] [Full Text] [Related]

  • 38. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
    Leenen FH, Myers MG, Joyner CD, Toal CB.
    Can J Cardiol; 2002 Dec 10; 18(12):1285-93. PubMed ID: 12518180
    [Abstract] [Full Text] [Related]

  • 39. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Shibasaki Y, Nishiue T, Masaki H, Matsubara H, Iwasaka T.
    Nihon Rinsho; 2002 Oct 10; 60(10):1992-8. PubMed ID: 12397697
    [Abstract] [Full Text] [Related]

  • 40. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW.
    N Engl J Med; 1998 Mar 05; 338(10):645-52. PubMed ID: 9486993
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.